TEM Tempus AI
Clinical and genomic data for AI diagnostics
Fundamentals from public market data, refreshed daily (2026-10-30 21:21 UTC). Figures in reporting currency.
TEM · price with what management and the data said
Timeline: management commentary, data & earnings
8 events-
8
2026-07-30EarningsBeat / raise
Reported EPS -0.04 vs -0.15 expected (+73.6% surprise).
-
7
2026-05-05EarningsBeat / raise
Reported EPS -0.13 vs -0.2 expected (+35.4% surprise).
-
6
2026-02-24EarningsBeat / raise
Reported EPS -0.04 vs -0.05 expected (+22.1% surprise).
-
5
2025-11-04EarningsBeat / raise
Reported EPS -0.11 vs -0.18 expected (+37.3% surprise).
-
4
2025-08-08EarningsBeat / raise
Reported EPS -0.22 vs -0.25 expected (+13.0% surprise).
-
3
2025-05-06EarningsBeat / raise
Reported EPS -0.24 vs -0.27 expected (+10.2% surprise).
-
2
2025-02-24EarningsMiss / cut
Reported EPS -0.18 vs -0.15 expected (-17.5% surprise).
-
1
2024-11-04EarningsBeat / raise
Reported EPS -0.25 vs -0.31 expected (+19.5% surprise).
Latest headlines
Auto-updated daily- Clinical Genomics Interpretation Platforms Global Market Report 2026 | Capitalize on AI and Cloud Growth Through 2030 with Thermo Fisher, Illumina, QIAGEN, and Tempus AI2026-10-30
- Clinical Genomics Sequencing, Biobank, and Database Services Global Market to 2035 | Capitalize on AI and Precision Medicine: Illumina, Thermo Fisher, BGI Genomics, Tempus AI2026-10-30
- TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now?2026-10-30
- Can You Still Buy Tempus AI Stock Today?2026-10-28
- Tempus AI (TEM) Could Be 5% Undervalued After Bristol Myers And Pathos Deals2026-10-27
- The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings2026-10-27
- Tempus AI (TEM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?2026-10-26
Earnings history
EPS vs expectations| Date | Expected EPS | Reported EPS | Surprise |
|---|---|---|---|
| 2026-07-30 | -0.15 | -0.04 | +73.6% |
| 2026-05-05 | -0.2 | -0.13 | +35.4% |
| 2026-02-24 | -0.05 | -0.04 | +22.1% |
| 2025-11-04 | -0.18 | -0.11 | +37.3% |
| 2025-08-08 | -0.25 | -0.22 | +13.0% |
| 2025-05-06 | -0.27 | -0.24 | +10.2% |
| 2025-02-24 | -0.15 | -0.18 | −17.5% |
| 2024-11-04 | -0.31 | -0.25 | +19.5% |
| 2024-08-06 | -1.79 | -0.63 | +64.8% |
About Tempus AI
Website ↗Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findin…
Models now design molecules and antibodies, but clinical trials are still the gate. Value accrues to platforms with wet-lab data and pharma partnerships.
What would prove us wrong. Weakens if AI-designed candidates fail in the clinic at rates no better than traditional discovery.
Who else supplies this
| Stock | Role | Last | 1D | 1M | YTD | Trend |
|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | AI drug discovery with NVIDIA-backed compute | $4.03 | −4.95% | −1.0% | −1.5% | |
| SDGR Schrödinger | Physics-plus-AI molecular design software | $27.14 | −9.50% | −10.9% | +51.8% | |
| ABSI Absci | Generative-AI antibody design | $11.13 | −8.02% | +3.5% | +218.9% | |
| ABCL AbCellera Biologics | AI-driven antibody discovery | $12.27 | −6.19% | −11.8% | +258.8% |
Not investment advice. Prices delayed and in local currency. Quotes in "double quotes" are verbatim as reported by the linked source; other commentary is our paraphrase. Earnings dates are estimates.